Viiv Healthcare UK Limited

HIV-1 Treatment in Antiretroviral-Naïve Adults

Clinical research includes oral and long-acting antiretroviral therapy options for adults newly diagnosed with HIV, with attention to viral suppression, treatment initiation, and regimen selection in people who have not previously received therapy.

  • Oral once-daily treatment regimens
  • Long-acting injectable ART
  • Viral suppression in treatment-naïve adults

Studies also examine comparative effectiveness between simplified dual-drug and standard multi-drug approaches in initial HIV-1 management.

Long-Acting and Switch-Based Maintenance Therapy

Research activity extends to maintaining virologic suppression after switching from established oral regimens to long-acting combinations, including injectable approaches for adults already living with controlled HIV infection.

  • Switch strategies after suppression
  • Two-monthly injectable combinations
  • Durability of treatment response

This area includes assessment of treatment choice and preference in adults considering oral versus injectable maintenance options.

Heavily Treatment-Experienced and Drug-Resistant HIV

The sponsor supports studies in adults with limited treatment options due to multidrug-resistant HIV-1 or prior antiretroviral exposure, including settings where current regimens are failing or no longer fully effective.

  • Drug-resistant HIV-1
  • Heavily treatment-experienced populations
  • Salvage and rescue treatment strategies

Research in this domain focuses on restoring antiviral control in people with complex treatment histories.

Novel Antiviral Agents and Regimen Innovation

Clinical work includes evaluation of new HIV therapies such as attachment inhibitors, capsid-targeting agents, and other oral compounds designed to expand treatment choices for both untreated and treatment-experienced adults.

  • Attachment inhibitor-based regimens
  • Capsid-directed antiviral candidates
  • Oral regimen development

These studies are directed toward improving antiviral activity and broadening options for HIV-1 management.

Reservoir and Immune-Based HIV Research

Additional research interest includes the viral reservoir and the use of broadly neutralizing antibodies alongside integrase inhibitor-based therapy in adults living with HIV.

  • Viral reservoir modulation
  • Broadly neutralizing antibodies
  • Combination approaches with integrase-based therapy

This area reflects interest in deeper virologic control beyond routine suppression.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Belgium France Germany Italy Poland Portugal +1
  • Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Germany Italy Portugal Spain
  • Study on the Safety and Effectiveness of Fostemsavir for Patients with Multi-drug Resistant HIV-1 Who Have Had Extensive Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Romania
  • Study on the Effects of VH4524184 for Adults Newly Diagnosed with HIV

    Not recruiting

    2 1
    Investigated drugs:
    Italy Spain
  • Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

    Not recruiting

    3 1 1 1
    Austria Belgium France Germany Italy The Netherlands +2
  • Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

    Not recruiting

    3 1 1 1
    France Germany Italy Spain